Sentence examples for evidence is developing from inspiring English sources

In their book "Raising Our Athletic Daughters" (Main Street Books, Doubleday, 1998), the authors Jean Zimmerman and Gil Reavill, a married couple living in Hastings-on-Hudson, write: "New evidence is developing which indicates that girls who play sports tend to avoid the physical, psychological and social pitfalls of modern adolescence.

Although general agreement exist supporting the risk of running too much too soon, and despite emerging evidence is developing for the relationship between training load and injury risk, knowledge of how to progress the half-marathon training load in relation to load capacity is still scientifically sparsely explored.

Scientific evidence is developing continuously and guidelines should therefore be changed according to the latest evidence on a regular basis.

4 Evidence is developing on the role of organisational interventions in improving the management of a range of chronic conditions.

Evidence is developing that suggests that the existing and widely used diagnostic system developed by Achenbach and colleagues contains the two subtypes under different labels.

A web of evidence is developing to substantiate the effectiveness of the implementation of specific musculoskeletal MoCs, as reported in our recent international review [ 21], as well as uptake at a jurisdictional level [ 22– 25].

If the case against them does not develop beyond what has been reported, and if no useable evidence is developed against the 24 other men, the decision to arrest will be second-guessed.

Until such evidence is developed, temporary IVC filters should be implanted based on best available evidence and routinely removed within the guidelines of the FDA of 25-54 days. 25-54 days

"It's always ongoing because whether a year from now or three years from now, evidence is developed or tips are called in or somebody comes to the FBI and informs us, 'Hey, I know who the bad guy is,'" he told me over the phone.

Typically, a bank of preclinical evidence is developed using cell lines, model organisms and clinical samples associating a target with key bioprocesses (and so disease phenotype).

It is critical to monitor these patterns as additional evidence is developed regarding the comparative effectiveness as well as potential risks of newer therapies, especially injectable incretin mimetics (GLP-1 agonists), DPP-4 inhibitors, and SGLT-2 inhibitors.